Deerfield Management and Janus Henderson Investors led a $107m Series B round in Synthekine, an engineered cytokine therapeutics company, with participation from RA Capital Management, Rock Springs Capital, Omega Funds, TCG X, Lilly Asia Ventures, The Column Group, Samsara BioCapital, Canaan Partners, and Emerson Collective. "Synthekine was founded two years ago to advance cytokine science and create optimized therapeutics in this important space. In that time, we have advanced two highly differentiated programs to IND-enabling development, expanded our pre-clinical pipeline of selective cytokine therapeutics through both internal development and licensing, and built a world-class team," Debanjan Ray, Synthekine CEO.